Abstract:Nano‐metformin, encapsulated within pectin nanoparticles, enhances the efficacy of metformin against colorectal cancer (CRC) cells. It exhibits significant dose‐dependent cytotoxicity, anti‐inflammatory effects, and induces apoptotic cell death by regulating key apoptotic markers. Nano‐metformin also causes DNA damage and reduces cell migration, presenting a promising therapeutic strategy for CRC treatment. Colorectal cancer (CRC) continues to be a significant health challenge, necessitating the development of efficient therapeutic strategies. Drug repurposing, which involves the use of existing medications for new purposes, presents a promising opportunity. Metformin, a widely used antidiabetic drug, has demonstrated potential anticancer effects. To enhance its efficacy, we formulated nano‐metformin, metformin encapsulated within pectin nanoparticles. Our study aimed to evaluate the superiority of nano‐metformin over free metformin in treating CRC. The cytotoxicity of both metformin and nano‐metformin on Caco‐2 CRC cells was assessed using the MTT assay, revealing a significant dose‐dependent inhibition of cell growth using nano‐metformin. The anti‐inflammatory potential was evaluated by measuring the levels of nitric oxide and the pro‐inflammatory cytokines IL‐2 and IL‐6 following lipopolysaccharide (LPS) induction, and the results revealed that treating LPS‐induced cells with nano‐metformin significantly reduced the production of these inflammatory mediators. To elucidate the mechanism of cell death, we employed an acridine orange/ethidium bromide staining assay, which revealed the enhancement of apoptotic cell death following treatment with nano‐metformin. Additionally, we examined the expression of key apoptotic regulators using real‐time qPCR. Nano‐metformin, in particular, significantly downregulated the expression of the antiapoptotic markers Bcl‐2 and Survivin while upregulating the proapoptotic caspases 3, 7, and 9. The comet assay revealed significant DNA damage induced by treatment with the nano‐metformin compared with that in the free form. Moreover, nano‐metformin significantly reduced the migration ability of cells. In conclusion, our work revealed the superior efficacy of our formulated nanoform over free metformin, highlighting its potential as a promising therapeutic agent for CRC treatment.

Repurposing metformin as adjuvant therapy in patients with ulcerative colitis treated with mesalamine: A randomized controlled double-blinded study

Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90/NLRP3 interaction and inducing autophagy in rats

Metformin Exerts Anti-inflammatory and Mucus Barrier Protective Effects by Enriching Akkermansia muciniphila in Mice With Ulcerative Colitis

Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis

Combined Diosmectite and Mesalazine Treatment for Mild-to-moderate Ulcerative Colitis: a Randomized, Placebo-Controlled Study.

Metformin Affects Gut Microbiota Composition and Diversity Associated with Amelioration of Dextran Sulfate Sodium-Induced Colitis in Mice

Metformin Alleviates Colitis-Associated Colorectal Cancer Via Inhibition of the TLR4/MyD88/NFκB/MAPK Pathway and Macrophage M2 Polarization

Metformin and Probiotics in the Crosstalk between Colitis-Associated Colorectal Cancer and Diabetes in Mice

The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome

Clinical study of mesalazine alone and in combination with steroids in treatment of ulcerative colitis

Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study

Oral Metformin and Polymetformin Reprogram Immunosuppressive Microenvironment and Boost Immune Checkpoint Inhibitor Therapy in Colorectal Cancer

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of randomized controlled trials

Preclinical Model for Combined Effects of Metformin and Vitamin D3 on Colitis-Associated Colon Neoplasia.

Effect of Combine Probiotics with Mesalazine on Ulcerative Colitis

Enhancing the anticancer effect of metformin through nanoencapsulation: Apoptotic induction, inflammatory reduction, and suppression of cell migration in colorectal cancer cells

Effectiveness of a novel diet in attenuation of clinical activity of disease in patients with ulcerative colitis: a randomized, clinical trial

The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial

Effect of Intestinal Microbiota Transplantation on Intestinal Flora and Inflammatory Factor Levels in Patients with Ulcerative Colitis

N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study